The research-based sector will argue any decision to maintain the secrecy of generic and biosimilar evaluations is discriminatory because it provides a commercial benefit and even a degree of legal protection to one part of the sector.
Research-based companies to argue discrimination on submission dates
August 12, 2019 Latest NewsNews of the DayLatest Video
New Stories
-
The Week in Review Podcast - 19 April
April 19, 2024 - - Podcast -
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 - - Latest News -
Scope of practice review recommends formation of new committee
April 19, 2024 - - Latest News -
The HTA review reference committee members should ask themselves one question
April 18, 2024 - - Latest News -
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News